Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (VRCA) is a clinical-stage leader in dermatology therapeutics, pioneering FDA-approved treatments for complex skin conditions. This page provides investors and healthcare professionals with essential updates on the company's advancements in medical dermatology.
Access real-time news about Verrica's clinical trials, regulatory milestones, and strategic partnerships. Our curated collection includes updates on YCANTH® (the first FDA-approved molluscum contagiosum therapy), pipeline developments like VP-315 for skin cancers, and critical business decisions affecting the dermatology sector.
Key coverage areas include FDA regulatory updates, clinical trial results, research collaborations, and market expansion strategies. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Verrica's latest developments in drug-device combination therapies and their impact on dermatological care. For comprehensive analysis of VRCA's position in medical dermatology, visit regularly for unfiltered updates directly from corporate communications and verified industry reports.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the FDA's acceptance of its resubmitted NDA for VP-102, targeting molluscum contagiosum, with a PDUFA goal date of June 23, 2021. The company also revealed that Torii Pharmaceutical will develop and commercialize VP-102 in Japan, with a potential $69.5 million in milestone payments. During Q4 2020, Verrica reported a net loss of $13 million, an increase from $7.6 million in Q4 2019. Full-year 2020 losses reached $42.7 million. Research and development expenses decreased to $2.3 million in Q4 2020. As of December 31, 2020, cash reserves totaled $65.5 million.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present a business overview at the H.C. Wainwright Annual Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand starting at 7:00 a.m. ET on March 9, 2021. The event can be accessed via a webcast link provided in the announcement and will also be available on the Verrica website. The company is focused on developing medications for skin diseases, including its late-stage product candidate VP-102, aimed at treating molluscum and warts.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced its participation in the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:50 a.m. ET, where CEO Ted White will present a business overview. Interested parties can access a live webcast through provided links, with a replay available for 30 days post-event. The company focuses on dermatology therapeutics, developing treatments for conditions like molluscum contagiosum and warts. Its key product candidates include VP-102 and VP-103, with a worldwide licensing agreement for LTX-315.
Verrica Pharmaceuticals announced that its resubmitted New Drug Application (NDA) for VP-102 (0.7% cantharidin topical solution) has been accepted by the FDA, with a PDUFA goal date of June 23, 2021. If approved, VP-102 could be the first FDA-approved treatment for molluscum contagiosum, a viral skin condition affecting around 6 million people in the U.S., mainly children. The NDA is based on positive Phase 3 clinical trial results showing significant clearance of molluscum lesions, with no serious adverse events reported.
Verrica Pharmaceuticals (Nasdaq: VRCA) has announced positive data from post-hoc analyses of its Phase 3 trials for VP-102, a treatment for molluscum contagiosum. Results showed significantly higher clearance rates of lesions across various body regions compared to the vehicle control, starting as early as Day 21. Additionally, in the Phase 2 CARE-1 study for external genital warts (EGW), VP-102 demonstrated a significantly higher clearance rate at Day 63 and Day 84. The FDA is currently reviewing VP-102, which may become the first approved treatment for molluscum contagiosum.
Verrica Pharmaceuticals (Nasdaq: VRCA) has resubmitted the New Drug Application (NDA) for its lead product, VP-102, aimed at treating molluscum contagiosum, a contagious skin disease affecting approximately six million people in the U.S., mainly children. The resubmission responds to a Type A meeting with the FDA and addresses concerns from a previous Complete Response Letter issued in July 2020. If approved, VP-102 will be the first FDA-approved treatment for this condition, marketed as YCANTH™.
Verrica Pharmaceuticals reaffirmed its expectation to resubmit the New Drug Application (NDA) for VP-102, targeting molluscum contagiosum, in Q1 2021. This announcement comes after productive discussions with the FDA addressing prior Chemistry, Manufacturing, and Controls (CMC) issues outlined in a Complete Response Letter received in July. VP-102 is a first-in-class drug-device combination aimed at treating a viral skin disease, currently lacking FDA-approved options. The company is also preparing to complete a Human Factors study by year-end.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present a business overview at the Jefferies Virtual London Healthcare Conference on November 17, 2020. The presentation will be accessible via live webcast on Verrica's website.
The company is developing VP-102, a potential first-in-class treatment for molluscum contagiosum, with plans to resubmit its NDA in early 2021 following feedback from the FDA. VP-102 has completed Phase 2 studies for common and external genital warts, and Verrica is also working on VP-103 for treating plantar warts.
Verrica Pharmaceuticals announced positive results from its Phase 2 CARE-1 study of VP-102, a topical therapy for external genital warts (EGW). 35% of subjects achieved complete clearance of treatable EGW by Day 84 compared to 2.4% for the vehicle (p=0.0001). The treatment was well-tolerated with no serious adverse events. Approximately 500,000 to 1 million new cases of EGW are diagnosed annually in the U.S. Based on these results, Verrica plans to request an End-of-Phase 2 meeting with the FDA in early 2021.
Verrica Pharmaceuticals (Nasdaq: VRCA) has completed a Type A meeting with the FDA regarding its New Drug Application (NDA) resubmission for VP-102, aimed at treating molluscum contagiosum. The resubmission is expected in Q1 2021 following positive feedback from the FDA. In Q3 2020, Verrica reported a net loss of $10.5 million, an increase from $6.1 million the previous year. R&D expenses rose to $5 million, largely due to higher manufacturing costs. As of September 30, 2020, the company held $71.9 million in cash and equivalents, sufficient to sustain operations through Q4 2021.
